UCB SA (OTCMKTS:UCBJY) Shares Shorted: Short Interest Down 63.8% in October

UCB SA (OTCMKTS:UCBJY – Get Free Report) saw a large decline in short interest in the month of October. As of October 30th, there was short interest totaling 7,614 shares, a decline of 63.8% from the October 15th total of 21,017 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 76,592 shares, the days-to-cover ratio is presently 0.1 days.

UCB Price Performance

OTCMKTS UCBJY opened at $163.75 on Monday. The business has a 50 day simple moving average of $131.08 and a 200 day simple moving average of $140.66. UCB has a 52-week low of $110.55 and a 52-week high of $168.76.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 27th. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy”.

Read Our Latest Analysis on UCB

About UCB

(Get Free Report)

UCB is a Belgian biopharmaceutical company headquartered in Brussels. Founded in 1928, it develops medicines for people with serious neurological and immune-mediated diseases, with research focused on areas such as epilepsy and inflammatory conditions. Its products include epilepsy treatments such as Briviact and Vimpat, as well as medicines for immune-mediated diseases, including Bimzelx and Cimzia. Product availability and approved uses vary by country. UCB serves patients and healthcare providers across international markets through its global operations.

See Also

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.